A PYMNTS Company

Lupin Subsidiary Reaches $30 Million Settlement With Humana While Denying Allegations

By  |  April 19, 2026

Pharmaceutical company Lupin Ltd announced on Friday that its U.S.-based subsidiary has agreed to a $30 million settlement with Humana Inc, even as it continues to deny all allegations tied to the case. The development comes amid ongoing litigation involving claims of anticompetitive practices in the generic drug industry.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to MSN, the settlement was reached by Lupin Pharmaceuticals, Inc. USA (LPI), a wholly owned arm of the Mumbai-based drugmaker, in connection with a broader legal dispute consolidated in the United States. The company clarified that such legal proceedings are not unusual in the pharmaceutical sector and are often resolved through negotiated agreements.

    “In the normal course of business, the Company and its subsidiaries are involved in legal proceedings, which are often resolved through settlement agreements with the plaintiffs. Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, we wish to inform that Lupin Pharmaceuticals, Inc. USA (LPI), a wholly owned subsidiary of the Company, has been involved in multiple civil lawsuits alleging anticompetitive behavior related to certain products and violation of federal and state antitrust laws,” the company said.

    Per MSN, these lawsuits were consolidated into a broader case known as In Re Generic Pharmaceuticals Antitrust Litigation, which is being handled in Philadelphia, Pennsylvania. The litigation includes multiple defendants across the generic pharmaceutical industry accused of engaging in price-fixing and other antitrust violations.

    Read more: US Appeals Court Revives Whistleblower Case Against Major Drugmakers Over Pricing Program

    “These multiple civil lawsuits were then combined into the collection of similar cases referred to as In Re Generic Pharmaceuticals Antitrust Litigation (Litigation), located in Philadelphia, Pennsylvania. While LPI denies the allegations but considering that other defendants have recently settled the case and in order to avoid the costs and uncertainties of continued Litigation, LPI has entered into a Settlement Agreement (Agreement) with one of the Plaintiffs namely Humana Inc,” Lupin added.

    The company confirmed that the agreement involves a payment of $30 million in exchange for a comprehensive release from claims brought by Humana. According to MSN, Lupin emphasized that the financial impact of the settlement had already been accounted for in its prior financial disclosures.

    “Under the terms of the Agreement, LPI will pay $30 million (US Dollars Thirty million) in consideration for a full and final release of all claims against LPI and its current and former parents, affiliates, directors, employees and officers by Humana. This amount of settlement has already been provided in the Company’s prior consolidated financial results,” the company also said.

    Despite agreeing to the settlement, Lupin reiterated that it does not admit to any wrongdoing. “The settlement explicitly states that LPI denies all allegations made against it, and that the Agreement does not imply any admission of liability or unlawful conduct by LPI,” Lupin further stated.

    Source: MSN